(Q36382231)

13 August 2017

1 reference

title

Hepatitis C -- identifying patients with progressive liver injury (English)

1 reference

13 August 2017

1 reference

Jordan J Feld

1

1 reference

PubMed ID

16447261

13 August 2017

T Jake Liang

series ordinal

2

1 reference

PubMed ID

16447261

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

43

1 reference

13 August 2017

2 Suppl 1

1 reference

13 August 2017

S194-206

1 reference

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

13 August 2017

1 reference

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

21 January 2018

1 reference

The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse

21 January 2018

1 reference

Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Testing for hepatitis C virus infection should be routine for persons at increased risk for infection

21 January 2018

1 reference

Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway.

21 January 2018

1 reference

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

21 January 2018

1 reference

7 January 2021

Acute hepatitis C: a multifaceted disease

1 reference

7 January 2021

The liver biopsy in chronic hepatitis C: a view from the other side of the microscope

1 reference

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

7 January 2021

Fibrosis progression in chronic hepatitis C virus infection

1 reference

7 January 2021

Progression of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

1 reference

7 January 2021

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

7 January 2021

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

1 reference

7 January 2021

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

1 reference

7 January 2021

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

7 January 2021

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

1 reference

7 January 2021

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

1 reference

7 January 2021

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

1 reference

7 January 2021

Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C.

1 reference

7 January 2021

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

1 reference

7 January 2021

Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children.

1 reference

7 January 2021

Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth

1 reference

7 January 2021

The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort

1 reference

7 January 2021

Merging models of hepatitis C virus pathogenesis

1 reference

7 January 2021

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

1 reference

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

7 January 2021

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

1 reference

7 January 2021

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

1 reference

7 January 2021

Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats

1 reference

7 January 2021

The impact of competing risks on the observed rate of chronic hepatitis C progression

1 reference

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

7 January 2021

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

1 reference

7 January 2021

Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women

1 reference

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

7 January 2021

Alcohol and hepatitis C

1 reference

7 January 2021

Hepatitis C virus infection in patients with clinically diagnosed alcoholic liver diseases

1 reference

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

7 January 2021

Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model

1 reference

7 January 2021

Impact of smoking on histological liver lesions in chronic hepatitis C.

1 reference

7 January 2021

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

1 reference

7 January 2021

Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection

1 reference

7 January 2021

Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study

1 reference

7 January 2021

Virological, immunological and histological aspects in adult beta-thalassemic patients with chronic hepatitis C virus infection

1 reference

7 January 2021

Hepatitis C, iron status, and disease severity: relationship with HFE mutations

1 reference

7 January 2021

HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis

1 reference

7 January 2021

Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C.

1 reference

7 January 2021

The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C

1 reference

7 January 2021

Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3.

1 reference

7 January 2021

Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus.

1 reference

7 January 2021

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial

1 reference

7 January 2021

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

7 January 2021

Pathophysiology of hepatitis C virus infection and related liver disease

1 reference

7 January 2021

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

7 January 2021

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

1 reference

7 January 2021

Care of patients with hepatitis C and HIV co-infection

1 reference

7 January 2021

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

7 January 2021

Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection

1 reference

7 January 2021

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

1 reference

7 January 2021

Long-term outcome of hepatitis C infection after bone marrow transplantation

1 reference

7 January 2021

Natural history of hepatitis C virus infection in adult renal graft recipients

1 reference

7 January 2021

1 reference

7 January 2021

Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.

1 reference

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

7 January 2021

Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus

1 reference

7 January 2021

A model to predict severe HCV-related disease following liver transplantation.

1 reference

7 January 2021

Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation

1 reference

7 January 2021

Steatosis: co-factor in other liver diseases.

1 reference

7 January 2021

Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always

1 reference

7 January 2021

Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets

1 reference

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

1 reference

7 January 2021

Steatosis affects chronic hepatitis C progression in a genotype specific way

1 reference

7 January 2021

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

7 January 2021

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

1 reference

7 January 2021

Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis

1 reference

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

7 January 2021

Fibrogenic impact of high serum glucose in chronic hepatitis C.

1 reference

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

7 January 2021

Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways

1 reference

7 January 2021

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

7 January 2021

Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation

1 reference

7 January 2021

Pathogenesis of steatohepatitis

1 reference

7 January 2021

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

7 January 2021

In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features

1 reference

7 January 2021

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

1 reference

7 January 2021

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

1 reference

7 January 2021

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression

1 reference

7 January 2021

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

1 reference

7 January 2021

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

1 reference

7 January 2021

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

1 reference

7 January 2021

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase

1 reference

7 January 2021

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

1 reference

7 January 2021

Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

1 reference

7 January 2021

Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study

1 reference

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

7 January 2021

Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C

1 reference

7 January 2021

Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.

1 reference

7 January 2021

High prevalence of occult hepatitis B in Baltimore injection drug users

1 reference

7 January 2021

Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen

1 reference

7 January 2021

The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C.

1 reference

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

7 January 2021

Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update

1 reference

7 January 2021

Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease

1 reference

7 January 2021

Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus

1 reference

7 January 2021

Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels

1 reference

7 January 2021

Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease

1 reference

7 January 2021

Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease

1 reference

7 January 2021

Host genetic determinants in hepatitis C virus infection

1 reference

7 January 2021

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

1 reference

7 January 2021

Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection

1 reference

7 January 2021

SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C.

1 reference

7 January 2021

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

1 reference

7 January 2021

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

1 reference

7 January 2021

A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease

1 reference

7 January 2021

The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection

1 reference

7 January 2021

No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.

1 reference

7 January 2021

Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection

1 reference

7 January 2021

Host genetic factors influence disease progression in chronic hepatitis C.

1 reference

7 January 2021

Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV.

1 reference

7 January 2021

Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus

1 reference

7 January 2021

Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease

1 reference

7 January 2021

Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection

1 reference

7 January 2021

A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C

1 reference

7 January 2021

Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses

1 reference

7 January 2021

Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein

1 reference

7 January 2021

Cytokines and fibrogenesis

1 reference

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

7 January 2021

Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model

1 reference

7 January 2021

Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury

1 reference

7 January 2021

Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice

1 reference

7 January 2021

Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses

1 reference

7 January 2021

Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells

1 reference

7 January 2021

Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection

1 reference

7 January 2021

Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21065

1 reference

13 August 2017

1 reference

PubMed ID

16447261